mRNA encoding norovirus VP1 produces antigenically functional virus-like particles in vitro
Summary
Human norovirus is a leading cause of acute gastroenteritis worldwide across all age groups, yet no licensed vaccine is available. The major capsid protein, VP1, self-assembles into highly immunogenic virus-like particles (VLPs) that have shown promise in clinical studies. Recently, mRNA has emerged as a compelling platform for norovirus vaccination. However, whether VP1-encoding mRNA can drive authentic VLP formation in human cells relevant to the vaccination environment has remained unknown.
Human norovirus is a leading cause of acute gastroenteritis worldwide across all age groups, yet no licensed vaccine is available. The major capsid protein, VP1, self-assembles into highly immunogenic virus-like particles (VLPs) that have shown promise in clinical studies. Recently, mRNA has emerged as a compelling platform for norovirus vaccination. However, whether VP1-encoding mRNA can drive authentic VLP formation in human cells relevant to the vaccination environment has remained unknown. In this study, we used multiple human cell lines, including THP-1-derived macrophage-like cells, to model the post-vaccination environment. Transfection with norovirus GII.4 VP1 mRNA or lipid nanoparticle-formulated VP1 mRNA induced both intracellular and extracellular VP1 expression. Sucrose gradient purification and electron microscopy confirmed VLP assembly. These particles retained key antigenic and functional properties, including recognition by norovirus-specific antibodies in human serum and binding to histo-blood group antigens. Collectively, our findings provide direct evidence that VP1-encoding mRNA can generate structurally and functionally relevant norovirus VLPs in physiologically relevant human cell systems. These results strengthen the mechanistic rationale for mRNA-based norovirus vaccines and support their continued development.
Abstract from PubMed (PMID 42933242). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols
Molecular pharmaceuticsCombined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy
The Journal of clinical investigationA single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
